[1]
|
中华医学会骨科学分会骨肿瘤学组. 中国骨巨细胞瘤临床诊疗指南[J]. 中华骨科杂志, 2018, 38(14): 833-840.
|
[2]
|
Balke, M., Schremper, L., Gebert, C., et al. (2008) Giant Cell Tumor of Bone: Treatment and Outcome of 214 Cases. Journal of Cancer Research and Clinical Oncology, 134, 969-978. https://doi.org/10.1007/s00432-008-0370-x
|
[3]
|
Dempster, D., Lambing, C., Kostenuik, P. and Grauer, A. (2012) Role of RANK Ligand and Denosumab, a Targeted RANK Ligand Inhibitor, in Bone Health and Osteoporosis: A Review of Preclinical and Clinical Data. Clinical Therapeutics, 34, 521-536. https://doi.org/10.1016/j.clinthera.2012.02.002
|
[4]
|
孙梓威, 吴哲宇, 张罗晟, 等. 地舒单抗在骨巨细胞瘤新辅助治疗中的应用研究进展[J]. 脊柱外科杂志, 2023, 21(3): 196-202.
|
[5]
|
沈艳, 杨通, 陈贵东, 等. 地舒单抗(Denosumab)治疗后骨巨细胞瘤假肉瘤样变伴有高核分裂活性的罕见组织形态特征分析[J]. 中国癌症防治杂志, 2023, 15(4): 406-410.
|
[6]
|
Basu Mallick, A. and Chawla, S.P. (2021) Giant Cell Tumor of Bone: An Update. Current Oncology Reports, 23, Article No. 51. https://doi.org/10.1007/s11912-021-01047-5
|
[7]
|
Campanacci, M., Baldini, N., Boriani, S., et al. (1987) Giant-Cell Tumor of Bone. Journal of Bone and Joint Surgery, 69, 106-114. https://doi.org/10.2106/00004623-198769010-00018
|
[8]
|
Li, B., Qian, M., Cao, H., et al. (2017) TGF-β2-Induced ANGPTL4 Expression Promotes Tumor Progression and Osteoclast Differentiation in Giant Cell Tumor of Bone. Oncotarget, 8, 54966-54977. https://doi.org/10.18632/oncotarget.18629
|
[9]
|
Wu, P.F., Tang, J. and Li, K. (2015) RANK Pathway in Giant Cell Tumor of Bone: Pathogenesis and Therapeutic Aspects. Tumor Biology, 36, 495-501. https://doi.org/10.1007/s13277-015-3094-y
|
[10]
|
Forsyth, R., De Boeck, G., Bockx, E. and Samson, I. (2009) CD33 CD14− Phenotype Is Characteristic of Multinuclear Osteoclast-Like Cells in Giant Cell Tumor of Bone. Journal of Bone and Mineral Research, 24, 70-77. https://doi.org/10.1359/jbmr.080905
|
[11]
|
Parmeggiani, A., Miceli, M., Errani, C., et al. (2021) State of the Art and New Concepts in Giant Cell Tumor of Bone: Imaging Features and Tumor Characteristics. Cancers, 13, Article 6298. https://doi.org/10.3390/cancers13246298
|
[12]
|
Montgomery, C., Couch, C., Emory, C.L., et al. (2019) Giant Cell Tumor of Bone: Review of Current Literature, Evaluation, and Treatment Options. The Journal of Knee Surgery, 32, 331-336. https://doi.org/10.1055/s-0038-1675815
|
[13]
|
Thomas, D.M. (2012) RANKL, Denosumab, and Giant Cell Tumor of Bone. Current Opinion in Oncology, 24, 397-403. https://doi.org/10.1097/CCO.0b013e328354c129
|
[14]
|
Thomas, D., Henshaw, R., Skubitz, K., et al. (2010) Denosumab in Patients with Giant-Cell Tumour of Bone: An Open-Label, Phase 2 Study. The Lancet Oncology, 11, 275-280. https://doi.org/10.1016/S1470-2045(10)70010-3
|
[15]
|
Martin-Broto, J., Cleeland, C.S., Glare, P.A., et al. (2014) Effects of Denosumab on Pain and Analgesic Use in Giant Cell Tumor of Bone: Interim Results from a Phase II Study. Acta Oncologica, 53, 1173-1179. https://doi.org/10.3109/0284186X.2014.910313
|
[16]
|
Ueda, T., Morioka, H., Nishida, Y., et al. (2015) Objective Tumor Response to Denosumab in Patients with Giant Cell Tumor of Bone: A Multicenter Phase II Trial. Annals of Oncology, 26, 2149-2154. https://doi.org/10.1093/annonc/mdv307
|
[17]
|
Enqellau, J., Chawla, S., Grimer, R., et al. (2011) Denosumab Treatment for Giant Cell Tumor of Bone (GCTB) in Adolescent Patients: Interim Results from a Phase II Study. European Journal of Cancer, 47, 15-16. https://doi.org/10.1016/S0959-8049(11)70131-9
|
[18]
|
Kato, I., Furuya, M., Matsuo, K., et al. (2018) Giant Cell Tumours of Bone Treated with Denosumab: Histological, Immunohistochemical and H3F3A Mutation Analyses. Histopathology, 72, 914-922. https://doi.org/10.1111/his.13448
|
[19]
|
Sahito, B., Ali, S.M.E., Kumar, D., et al. (2022) Role of Denosumab before Resection and Reconstruction in Giant Cell Tumors of Bone: A Single-Centered Retrospective Cohort Study. European Journal of Orthopaedic Surgery & Traumatology, 32, 567-574. https://doi.org/10.1007/s00590-021-03012-1
|
[20]
|
Lim, C.Y., Liu, X., He, F., et al. (2020) Retrospective Cohort Study of 68 Sacral Giant Cell Tumours Treated with Nerve-Sparing Surgery and Evaluation on Therapeutic Benefits of Denosumab Therapy. The Bone & Joint Journal, 102, 177-185. https://doi.org/10.1302/0301-620X.102B2.BJJ-2019-0813.R1
|
[21]
|
Ferrari, S., Rutkowski, P., Grimer, R.J., et al. (2014) Assessment of Surgical Downstaging in an Open-Label Phase 2 Trial of Denosumab in Patients with Giant Cell Tumor of Bone. Annals of Oncology, 25, iv494-iv510. https://doi.org/10.1093/annonc/mdu354.8
|
[22]
|
Deveci, M.A., Paydaş, S., Gönlüşen, G., et al. (2017) Clinical and Pathological Results of Denosumab Treatment for Giant Cell Tumors of Bone: Prospective Study of 14 Cases. Acta Orthopaedica et Traumatologica Turcica, 51, 1-6. https://doi.org/10.1016/j.aott.2016.03.004
|
[23]
|
Asano, N., Saito, M., Kobayashi, E., et al. (2022) Preoperative Denosumab Therapy against Giant Cell Tumor of Bone Is Associated with an Increased Risk of Local Recurrence after Curettage Surgery. Annals of Surgical Oncology, 29, 3992-4000. https://doi.org/10.1245/s10434-022-11411-9
|
[24]
|
Asano, N. and Horiuchi, K. (2022) ASO Author Reflections: Preoperative Denosumab May Increase the Risk of Local Recurrence of Giant Cell Tumor of Bone after Curettage Surgery. Annals of Surgical Oncology, 29, 4001. https://doi.org/10.1245/s10434-022-11430-6
|
[25]
|
Gaston, C.L., Grimer, R.J., Parry, M., et al. (2016) Current Status and Unanswered Questions on the Use of Denosumab in Giant Cell Tumor of Bone. Clinical Sarcoma Research, 6, Article No. 15. https://doi.org/10.1186/s13569-016-0056-0
|
[26]
|
Errani, C., Tsukamoto, S., Leone, G., et al. (2018) Denosumab May Increase the Risk of Local Recurrence in Patients with Giant-Cell Tumor of Bone Treated with Curettage. Journal of Bone and Joint Surgery, 100, 496-504. https://doi.org/10.2106/JBJS.17.00057
|
[27]
|
Chawla, S., Blay, J.Y., Rutkowski, P., et al. (2019) Denosumab in Patients with Giant-Cell Tumour of Bone: A Multicentre, Open-Label, Phase 2 Study. The Lancet Oncology, 20, 1719-1729. https://doi.org/10.1016/S1470-2045(19)30663-1
|
[28]
|
Palmerini, E., Staals, E.L., Jones, L.B., et al. (2020) Role of (Neo) Adjuvant Denosumab for Giant Cell Tumor of Bone. Current Treatment Options in Oncology, 21, Article No. 68. https://doi.org/10.1007/s11864-020-00766-4
|
[29]
|
Mak, I.W.Y., Evaniew, N., Popovic, S., et al. (2014) A translational study of the neoplastic cells of giant cell tumor of bone following neoadjuvant denosumab. Journal of Bone and Joint Surgery, 96, e127. https://doi.org/10.2106/JBJS.M.01332
|
[30]
|
Traub, F., Singh, J., Dickson, B.C., et al. (2016) Efficacy of Denosumab in Joint Preservation for Patients with Giant Cell Tumour of the Bone. European Journal of Cancer, 59, 1-12. https://doi.org/10.1016/j.ejca.2016.01.006
|
[31]
|
Campanacci, L., Sambri, A., Medellin, M.R., et al. (2019) A New Computerized Tomography Classification to Evaluate Response to Denosumab in Giant Cell Tumors in the Extremities. Acta Orthopaedica et Traumatologica Turcica, 53, 376-380. https://doi.org/10.1016/j.aott.2019.05.005
|
[32]
|
Chawla, S., Henshaw, R., Seeger, L., et al. (2013) Safety and Efficacy of Denosumab for Adults and Skeletally Mature Adolescents with Giant Cell Tumour of Bone: Interim Analysis of an Open-Label, Parallel-Group, Phase 2 Study. The Lancet Oncology, 14, 901-908. https://doi.org/10.1016/S1470-2045(13)70277-8
|
[33]
|
Niu, X., Yang, Y., Wong, K.C., et al. (2019) Giant Cell Tumour of the Bone Treated with Denosumab: How Has the Blood Supply and Oncological Prognosis of the Tumour Changed? Journal of Orthopaedic Translation, 18, 100-108. https://doi.org/10.1016/j.jot.2018.10.003
|
[34]
|
Yang, Y., Li, Y., Liu, W., et al. (2018) A Nonrandomized Controlled Study of Sacral Giant Cell Tumors with Preoperative Treatment of Denosumab. Medicine, 97, e13139. https://doi.org/10.1097/MD.0000000000013139
|
[35]
|
Schreuder, W.H., Lipplaa, A., Cleven, A.H.G., et al. (2022) RANKL Inhibition for Giant Cell Lesions of the Jaw: A Retrospective Cohort Analysis. European Journal of Cancer, 175, 263-273. https://doi.org/10.1016/j.ejca.2022.08.011
|
[36]
|
Urakawa, H., Nagano, A., Machida, R., et al. (2022) A Randomized Phase III Trial of Denosumab before Curettage for Giant Cell Tumor of Bone. JCOG1610. Japanese Journal of Clinical Oncology, 52, 1021-1028. https://doi.org/10.1093/jjco/hyac071
|
[37]
|
Xiang, F., Liu, H., Deng, J., et al. (2022) Progress on Denosumab Use in Giant Cell Tumor of Bone: Dose and Duration of Therapy. Cancers, 14, Article 5758. https://doi.org/10.3390/cancers14235758
|
[38]
|
van der Heijden, L., Dijkstra, P.D.S., Blay, J.Y., et al. (2017) Giant Cell Tumour of Bone in the Denosumab Era. European Journal of Cancer, 77, 75-83. https://doi.org/10.1016/j.ejca.2017.02.021
|
[39]
|
Rhou, Y.J.J., Wang, C.J., Nguyen, M., et al. (2022) Clinical and Radiologic Response of Central Giant Cell Granuloma to Denosumab: A 6-Year Prospective Observational Study. Calcified Tissue International, 110, 464-474. https://doi.org/10.1007/s00223-021-00935-z
|
[40]
|
Boye, K., Jebsen, N.L., Zaikova, O., et al. (2017) Denosumab in Patients with Giant-Cell Tumor of Bone in Norway: Results from a Nationwide Cohort. Acta Oncologica, 56, 479-483. https://doi.org/10.1080/0284186X.2016.1278305
|